DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth
Abstract
Background and aims: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current treatments. Targeted therapies may offer a new avenue for more effective strategies. Dual-specificity tyrosine regulated kinase 1A (DYRK1A) is a pleiotropic kinase with contradictory roles in different tumours that is uncharacterised in PDAC. Here, we aimed to investigate the role of DYRK1A in pancreatic tumorigenesis. Design: We analysed DYRK1A expression in PDAC genetic mouse models and in patient samples. DYRK1A function was assessed with knockdown experiments in pancreatic tumour cell lines and in PDAC mouse models with genetic reduction of Dyrk1a dosage. Furthermore, we explored a mechanistic model for DYRK1A activity. Results: We showed that DYRK1A was highly expressed in PDAC, and that its protein level positively correlated with that of c-MET. Inhibition of DYRK1A reduced tumour progression by limiting tumour cell proliferation. DYRK1A stabilised the c-MET receptor through SPRY2, leading to prolonged activation of extracellular signal-regulated kinase signalling. Conclusions: These findings reveal that DYRK1A contributes to tumour growth in PDAC, at least through regulation of c-MET accumulation, suggesting that inhibition of DYRK1A could represent a novel therapeutic target for PDAC.Keywords
Funding Information
- Generalitat de Catalunya
- Instituto de Salud Carlos III
- CIBER de Enfermedades Raras and de Enfermedades Hepáticas y Digestivas are initiatives of the Instituto de Salud Carlos III
- COST action
- Spanish Ministry of Economía, Industria y Competitividad
- Generalitat de Catalunya
- Ministerio de Economía y Competitividad
This publication has 46 references indexed in Scilit:
- Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growthJournal of Clinical Investigation, 2013
- EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndromeJournal of Clinical Investigation, 2012
- The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancerInternational Journal of Oncology, 2011
- Epidermal Growth Factor Receptor in Pancreatic CancerCancers, 2011
- Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomasOncogene, 2010
- Synergistic role of sprouty2 inactivation and c‐Met up‐regulation in mouse and human hepatocarcinogenesis†Hepatology, 2010
- Sprouty2-Mediated Inhibition of Fibroblast Growth Factor Signaling Is Modulated by the Protein Kinase DYRK1AMolecular and Cellular Biology, 2008
- Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic AnalysesScience, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007